Tim McCarthy, CEO of ImmuPharma talks to Proactive Investor following the recent Corporate Update, outlining the broadening of the portfolio and re-emphasising the Board’s focus on delivering near term shareholder value on its key assets including moving Lupuzor into its Phase 3 trial

22nd November 2021 - 3:18 pm
Share this article